The 4 Wall Street analysts covering Latigo Biotherapeutics, Inc. hold a median 12-month price target of $50 — +258.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 31 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Latigo Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (45): Smaller than most of the companies we track.
Momentum (1): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on LTGO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +258.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Sept 2026 | Guggenheim | Initiates | Buy | $50 |
| 1 Sept 2026 | Jefferies | Initiates | Buy | $50 |
| 1 Sept 2026 | Leerink Partners | Initiates | Outperform | $36 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
LTGO appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 96% of US stocks
Cheaper than 86% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 93% of US stocks
Higher than 1% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Latigo Biotherapeutics, Inc. has a market value of $924.9M and an enterprise value of $1.2B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$95.5M.
Free cash flow in the twelve months to 30 June 2026: −$91.3M.
Trailing P/E: −5.6×; forward P/E: −6.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Latigo Biotherapeutics, Inc. employs 66 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Latigo Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha characterized Latigo as undervalued below its IPO price, citing onzotrigine’s acute-pain data, pivotal-eligible Phase 2 results, and funding into 2029. It identified the Phase 3 bunionectomy trial as the key upcoming event.
Why it matters — LTGO watchers may focus on the Phase 3 trial because its results could test the case presented in the article.
Latigo Biotherapeutics reported its second quarter 2026 financial results, noting the completion of an upsized initial public offering that raised $397.4 million in gross proceeds, which together with existing cash is expected to fund operations into 2029. The company also highlighted the publication of positive onzotrigine abdominoplasty clinical trial results in The New England Journal of Medicine and the appointment of Naomi Lowy, M.D. as senior vice president of global regulatory affairs.
Why it matters — These developments signal extended financial runway, a key clinical validation from a top-tier publication, and strengthened regulatory expertise as Latigo advances its lead pain candidate.
Latigo Biotherapeutics (NASDAQ:LTGO) went public, receiving a strong reception from the market. The company is focused on developing a non-opioid pain treatment.
Why it matters — The IPO's warm welcome signals investor appetite for Latigo's non-opioid pain approach, making the company's public-market debut a notable event for LTGO watchers.
The 4 Wall Street analysts covering Latigo Biotherapeutics, Inc. have a median 12-month price target of $50, with estimates ranging from $36 to $73. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Latigo Biotherapeutics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Latigo Biotherapeutics, Inc. 1 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Latigo Biotherapeutics, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (45 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +258.4% from the last close, and Ticker Nerd's factor model ranks Latigo Biotherapeutics, Inc. 1 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Latigo Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LTGO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $36 to $73 over the next 12 months.
Latigo Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid pain medicines.
The most recent item we track (Seeking Alpha, 11 Oct 2026): "Vertex Built The NaV1.8 Market, Latigo May Be The One To Profit From It". Seeking Alpha characterized Latigo as undervalued below its IPO price, citing onzotrigine’s acute-pain data, pivotal-eligible Phase 2 results, and funding into 2029. It identified the Phase 3 bunionectomy trial as the key upcoming event.
Latigo Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid pain medicines. Its current programs are built around NaV1.8 inhibitors, a class of compounds designed to interrupt pain signaling at its source while avoiding the addiction risks associated with opioid therapies. The company’s pipeline includes candidates for acute pain, chronic musculoskeletal pain, and broader acute and chronic pain applications, with oral and intravenous formulations in development. Latigo Biotherapeutics serves the pain-management market by advancing targeted therapies intended for use in settings such as postoperative care, musculoskeletal disorders, and other medically significant pain conditions. Headquartered in Thousand Oaks, California, the company operates within the biotechnology sector and is centered on creating differentiated treatments that address unmet needs in non-opioid pain control.
CEO Mr. Nima Farzan M.B.A. · 66 employees · United States · https://latigobio.com
